229 related articles for article (PubMed ID: 31182532)
1. A Revised Species Concept for Opportunistic
Wagner L; de Hoog S; Alastruey-Izquierdo A; Voigt K; Kurzai O; Walther G
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182532
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.
Arendrup MC; Jensen RH; Meletiadis J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7735-42. PubMed ID: 26438494
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.
Chowdhary A; Kathuria S; Singh PK; Sharma B; Dolatabadi S; Hagen F; Meis JF
Mycoses; 2014 Dec; 57 Suppl 3():97-107. PubMed ID: 25250768
[TBL] [Abstract][Full Text] [Related]
4. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.
Vitale RG; de Hoog GS; Schwarz P; Dannaoui E; Deng S; Machouart M; Voigt K; van de Sande WW; Dolatabadi S; Meis JF; Walther G
J Clin Microbiol; 2012 Jan; 50(1):66-75. PubMed ID: 22075600
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States.
Badali H; Cañete-Gibas C; McCarthy D; Patterson H; Sanders C; David MP; Mele J; Fan H; Wiederhold NP
J Clin Microbiol; 2021 Aug; 59(9):e0123021. PubMed ID: 34232068
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.
Chowdhary A; Singh PK; Kathuria S; Hagen F; Meis JF
Antimicrob Agents Chemother; 2015 Dec; 59(12):7882-7. PubMed ID: 26438489
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure.
Escribano P; Mesquida A; López-Montesinos S; Reigadas E; Muñoz P; Guinea J
Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37113026
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.
Vanathi M; Naik R; Sidhu N; Ahmed NH; Gupta N; Tandon R
Indian J Ophthalmol; 2022 Dec; 70(12):4270-4283. PubMed ID: 36453329
[TBL] [Abstract][Full Text] [Related]
9. Drug combinations against Mucor irregularis in vitro.
Zhang S; Li R; Yu J
Antimicrob Agents Chemother; 2013 Jul; 57(7):3395-7. PubMed ID: 23587956
[TBL] [Abstract][Full Text] [Related]
10. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis.
Gupta P; Malhotra HS; Saxena P; Singh R; Shukla D; Hasan MS; Verma V; Banerjee G; Puri B; Dandu H
J Investig Med; 2022 Apr; 70(4):914-918. PubMed ID: 35078866
[TBL] [Abstract][Full Text] [Related]
11. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.
Espinel-Ingroff A; Chakrabarti A; Chowdhary A; Cordoba S; Dannaoui E; Dufresne P; Fothergill A; Ghannoum M; Gonzalez GM; Guarro J; Kidd S; Lass-Flörl C; Meis JF; Pelaez T; Tortorano AM; Turnidge J
Antimicrob Agents Chemother; 2015 Mar; 59(3):1745-50. PubMed ID: 25583714
[TBL] [Abstract][Full Text] [Related]
12. Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.
Maurer E; Hörtnagl C; Lackner M; Grässle D; Naschberger V; Moser P; Segal E; Semis M; Lass-Flörl C; Binder U
Med Mycol; 2019 Apr; 57(3):351-362. PubMed ID: 29924357
[TBL] [Abstract][Full Text] [Related]
13. Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran.
Vaezi A; Walther G; Kurzai O; Mahdi D; Dadashzadeh M; Nasri E; Diba K; Badali H; Fakhim H
Mycoses; 2021 Jul; 64(7):780-787. PubMed ID: 33835599
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.
Gregson L; Goodwin J; Johnson A; McEntee L; Moore CB; Richardson M; Hope WW; Howard SJ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5778-80. PubMed ID: 24041890
[TBL] [Abstract][Full Text] [Related]
17. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
González GM
Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.
Borman AM; Fraser M; Patterson Z; Palmer MD; Johnson EM
J Fungi (Basel); 2021 Apr; 7(4):. PubMed ID: 33918216
[TBL] [Abstract][Full Text] [Related]
20. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
Alastruey-Izquierdo A; Castelli MV; Cuesta I; Monzon A; Cuenca-Estrella M; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2009 Apr; 53(4):1686-9. PubMed ID: 19171801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
